Stryker Corporation $SYK Stock Holdings Lifted by Wellington Management Group LLP

Wellington Management Group LLP grew its position in Stryker Corporation (NYSE:SYK) by 0.6% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 8,167,185 shares of the medical technology company’s stock after purchasing an additional 45,478 shares during the period. Wellington Management Group LLP owned about 2.13% of Stryker worth $2,571,357,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently made changes to their positions in SYK. VanderPol Investments L.L.C. grew its stake in shares of Stryker by 1.4% in the 4th quarter. VanderPol Investments L.L.C. now owns 2,084 shares of the medical technology company’s stock valued at $732,000 after buying an additional 28 shares in the last quarter. KCM Investment Advisors LLC raised its position in Stryker by 1.5% during the fourth quarter. KCM Investment Advisors LLC now owns 1,857 shares of the medical technology company’s stock valued at $653,000 after acquiring an additional 28 shares in the last quarter. Rossby Financial LCC raised its position in Stryker by 6.6% during the fourth quarter. Rossby Financial LCC now owns 451 shares of the medical technology company’s stock valued at $159,000 after acquiring an additional 28 shares in the last quarter. Tcfg Wealth Management LLC lifted its stake in Stryker by 2.7% in the third quarter. Tcfg Wealth Management LLC now owns 1,091 shares of the medical technology company’s stock valued at $403,000 after acquiring an additional 29 shares during the last quarter. Finally, ICW Investment Advisors LLC grew its position in Stryker by 0.6% in the fourth quarter. ICW Investment Advisors LLC now owns 5,096 shares of the medical technology company’s stock worth $1,791,000 after acquiring an additional 30 shares in the last quarter. 77.09% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of research analysts have recently weighed in on the stock. Sanford C. Bernstein set a $410.00 price target on shares of Stryker in a report on Friday, May 1st. Argus set a $370.00 price objective on shares of Stryker in a report on Thursday, July 9th. Citizens Jmp lowered their target price on shares of Stryker from $440.00 to $400.00 and set a “market outperform” rating on the stock in a research report on Monday, August 3rd. Truist Financial raised their target price on Stryker from $330.00 to $340.00 and gave the company a “hold” rating in a report on Friday, July 31st. Finally, Needham & Company LLC decreased their price target on Stryker from $454.00 to $418.00 and set a “buy” rating for the company in a research note on Friday, May 1st. One analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and six have issued a Hold rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $386.28.

Stryker Price Performance

NYSE SYK opened at $331.32 on Friday. Stryker Corporation has a 1 year low of $281.00 and a 1 year high of $396.86. The company has a fifty day simple moving average of $329.10 and a 200 day simple moving average of $331.47. The company has a current ratio of 2.16, a quick ratio of 1.33 and a debt-to-equity ratio of 0.59. The company has a market cap of $127.08 billion, a P/E ratio of 34.33, a P/E/G ratio of 2.05 and a beta of 0.76.

Stryker (NYSE:SYK) last announced its earnings results on Thursday, July 30th. The medical technology company reported $3.69 EPS for the quarter, topping the consensus estimate of $3.49 by $0.20. The firm had revenue of $6.59 billion for the quarter, compared to the consensus estimate of $6.58 billion. Stryker had a net margin of 14.43% and a return on equity of 23.63%. The business’s quarterly revenue was up 9.4% on a year-over-year basis. During the same quarter last year, the firm posted $3.13 EPS. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. On average, sell-side analysts predict that Stryker Corporation will post 15.02 EPS for the current year.

Stryker Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, October 30th. Stockholders of record on Wednesday, September 30th will be paid a $0.88 dividend. The ex-dividend date is Wednesday, September 30th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 1.1%. Stryker’s payout ratio is presently 36.48%.

Insider Buying and Selling

In related news, Director Ronda E. Stryker sold 300,000 shares of the business’s stock in a transaction dated Tuesday, August 18th. The stock was sold at an average price of $335.90, for a total transaction of $100,770,000.00. Following the completion of the transaction, the director owned 2,301,375 shares of the company’s stock, valued at approximately $773,031,862.50. The trade was a 11.53% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Debra King sold 826 shares of the stock in a transaction that occurred on Tuesday, August 18th. The shares were sold at an average price of $336.30, for a total value of $277,783.80. Following the sale, the insider owned 6,210 shares of the company’s stock, valued at approximately $2,088,423. The trade was a 11.74% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders sold 351,267 shares of company stock valued at $118,197,701. Insiders own 4.60% of the company’s stock.

Stryker Company Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.